Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cervical smear DNA may reveal ovarian cancer years before symptoms

NCT ID NCT07821879

Diagnosis Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

High-grade serous ovarian cancer is often found too late, and no screening test exists. Researchers are studying whether DNA taken from routine cervical smears can show signs of this cancer early. They use a method called shallow-coverage whole genome sequencing to look for genomic instability in the DNA. The trial enrolls 50 patients already diagnosed with the disease to see if the test matches results from their tumor tissue.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
shallow-coverage whole genome sequencing of DNA from liquid-based cervical smears
What this could lead to
If it works, this approach could give doctors a non-invasive way to spot ovarian cancer years earlier, when treatment works best.
What could go wrong
The study is small and only looks at people already diagnosed with ovarian cancer, so it cannot yet show whether the test finds cancer in healthy people or catches it early enough to save lives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women with high grade serous ovarian carcinoma treated at Toulouse university of cancer-Oncopole.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients : * With high-grade serous ovarian carcinoma treated at the IUCT-O * For whom initial surgery (diagnostic or cytoreductive) is planned Exclusion Criteria: Patients with : * Concurrent endometrial or cervical cancer * History of cancer within the last two years * History of gynaecological cancer * History of salpingectomy, hysterectomy or trachelectomy (removal of the cervix)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer screening are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Genomic Instability ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer screening Genomic instability High grade serous ovarian cancer Whole genome sequencing

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institut Claudius Regaud

    RECRUITING

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.